MEDICIS PHARMACEUTICAL CORP

Operating margin

25.4%

Net margin

2.7%

Return on equity

2.3%

Return on assets

1.3%

Return on capital (ROCE)

20.9%

Liabilities / assets

—

Debt / equity

—

Book value / share

$12.45

Revenue growth (YoY)

3.6%

Net income growth (YoY)

−45.3%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

−10.5%clean

Piotroski F-Score

3/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• THEOLAIRMay 30, 1980

• Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 11, 2012
• Shareholder voteDec 10, 2012
• Other material eventDec 5, 2012
• Other material eventNov 28, 2012
• Other material eventNov 21, 2012
• Other material eventNov 16, 2012
• Other material eventNov 5, 2012
• Other material eventOct 17, 2012

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.